| January 24, 2003 |
| HEMISPHERX ANNOUNCES TAGLICH BROTHERS RELEASE OF UPDATED RESEARCH REPORT |
Philadelphia, PA, Friday, January 24, 2003: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today the issuance on January 22, 2003 by Taglich Brothers an update to their research report dated September 24, 2002.
Interested parties may view the updated report on Taglich Brothers website at www.TaglichBrothers.com.
ABOUT HEMISPHERX
Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information, on Hemispherx, please visit the company's Web site at www.hemispherx.net.
Contact(s):
Hemispherx Biopharma, Inc., Investor Relations
Dianne Will
(518) 398-6222, Fax: (518) 398-6223
Wesley Stanton, MRB Investors, Relations
(212) 495-0200, Fax: (212) 495-0746
MEDIA:
Robin Wagge, Rubenstein Associates, Inc.
(212) 843-8006
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. By publishing this press release, the Company in no way endorses any of the factual recitals or conclusions contained in the subject research report by Taglich Brothers. The Company refers all readers to its publicly filed information as well as its website for base reference. |
|
